Investing Ideas
/
Austrian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Austrian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

1 companies

Marinomed Biotech

Market Cap: €9.0m

Operates as a biopharmaceutical company in Austria, other European countries, and internationally.

MARI

€4.50

-6.3%

-77.3%